Type 2 & other diabetes

Short- and long-term mortality in patients with type 2 diabetes after myocardial infarction– a nationwide registry study

Cardiovasc DiabetolPublished Retrospective nationwide registry cohort study

Main finding · MortalityResult — go to the resultHazard ratio 1.20 95% CI 1.17–1.24

Authors' conclusion

Type 2 diabetes had a negative impact on both short- and long-term outcome after MI, but effect sizes were relatively small. Patients with longer duration of diabetes or need for insulin therapy are still at particular risk.

Study context

Population
Consecutive myocardial infarction (MI) patients treated in Finland 2004–2018; T2D: 40% female, mean age 73.6 yearspropensity score-matched
Participants
13,152 vs 77,669
Exposure
T2D vs no diabetes after MI
  • T2Dn = 13,152
  • No diabetesn = 77,669reference
Outcome
Mortality
Follow-up
30 days, 1 year and 15 years after MI (median 5.7 years)
Methodological detailspropensity score matching, multivariable adjustment, national registries
  • Propensity score matching
  • Multivariable adjustment
  • National registries

Main finding

As reported in the abstract

15 years

Hazard ratio

1.20

95% CI 1.17–1.24

P < 0.0001

By group

T2Dvs No diabetes
HR 1.20 (95% CI 1.17–1.24); P < 0.0001

Observational data: associations, not effects.

Further findings

Mortality · 30 days · propensity score-matched controls

P = 0.013

Mortality · 1 year · propensity score-matched controls

P = 0.001

Subgroups and predictors of mortality in T2D

T2D associated with poorer prognosis across the spectrum of MI patients
Excess mortality risk attenuated by increasing age; similar in both sexes
Male sex, age, CV and non-CV comorbidities, lack of revascularization, longer diabetes duration and baseline insulin therapy associated with increased mortality in T2D
1-year prognosis in T2D improved over study period; mortality gap vs no diabetes not altered

Original publication

Short- and long-term mortality in patients with type 2 diabetes after myocardial infarction– a nationwide registry study. Cardiovasc Diabetol. Published 30 October 2024. doi:10.1186/s12933-024-02479-6

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.